Invest In Biomed is a unique Eurobiomed program that assists innovative health companies in consolidating their fundraising approach and tools, and connects them with specialized investors in the sector. On the occasion of the launch of the 10th edition of this program, we are featuring entrepreneurs who have benefited from it.
Amaury Ciurana, CEO and co-founder of REEV, reflects on his experience with Eurobiomed's Invest In Biomed program, which supports health startups in their financing and fundraising strategies. His company, which develops a lightweight and intelligent motorization for medical orthoses to facilitate daily mobility, participated in the program in 2022, subsequently completing a first fundraising round of €3M in 2023, followed by a second round of €8.8M in early 2025.
What were the tangible outcomes of your participation in the Invest In Biomed program?
Amaury Ciurana: Our participation in the program at the end of 2022 was significant for our financing journey. Notably, we met one of our future investors there, who subsequently became the lead investor for our initial fundraising round in early 2023.
This initial encounter marked the beginning of a lasting collaboration, as this investor continues to support us as a lead investor in our development today, particularly during our second fundraising round in early 2025.
How was the support structured for preparing your fundraising journey?
Amaury Ciurana : The Eurobiomed team supported us through several dedicated workshops focused on preparing and optimizing our fundraising strategy. This preparatory phase culminated in a presentation in Marseille before a panel of investors, which was exceptionally well-received.
Although our presentation has naturally evolved since then, the strategy and mission we defined at the time have remained consistent, demonstrating the continued relevance of the work accomplished.
In your opinion, what is the program's primary added value?
Amaury Ciurana : The true strength of Invest In Biomed lies in its ability to foster an environment conducive to establishing trusting relationships with investors. The program provides a structured framework where entrepreneurs can present their projects in person, a practice that is becoming increasingly rare in current fundraising processes.
It provides the opportunity to meet investors who are already familiar with the health sector and recognize the added value of Eurobiomed's selection process. From that point, it is incumbent upon the entrepreneur to cultivate these initial connections, as we successfully demonstrated.
SIMILAR ARTICLES:
Arnaud Debains and Sandrine Isz (BOYDSense): 'Invest In Biomed enabled us to better articulate our story.'
Philippe Andres (Tarian Pharma): 'Invest In Biomed's support enabled us to adapt our communication to investors' expectations.'
